WHWK News & Events

Whitehawk Therapeutics announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure related homolog protein 6 with a next-generation ADC for the treatment of neuroendocrine tumors, including small cell lung cancer. These data will be presented in a poster at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting, being held May 29-June 2, 2026, in Chicago, Illinois. "SEZ6 demonstrates a compelling expression profile across SCLC and other neuroendocrine malignancies. In SCLC, it has levels of expression that are consistently high across disease stages and metastatic settings," said Afshin Dowlati, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University. "The magnitude of SEZ6 expression relative to other therapeutic targets, along with its enrichment in neuroendocrine-high SCLC subtypes, supports its potential as an ADC target."

Whitehawk Therapeutics entered into a new option agreement with Hangzhou DAC for access to CPT113 for use in up to five additional antibody drug conjugate, or ADC, programs. Whitehawk's ADC platform leverages CPT113 as the core linker-payload technology, adding its own proprietary Carbon Bridge Cysteine Re-pairing, or CBCR, bioconjugation process to support improved stability and therapeutic index. Whitehawk will select targets and source antibodies, while retaining global rights and full program control for the new ADC programs. Whitehawk anticipates submitting Investigational New Drug applications for multiple new programs over the next 12-24 months. Hangzhou DAC's DXC006 is a CD56-directed ADC that utilizes CPT113. DXC006 is being evaluated in first-in-human Phase 1 dose escalation/expansion study in China in solid tumor populations. Data from DXC006 were accepted for oral presentation at the American Society of Clinical Oncology Annual Meeting. The abstract points to clinical activity and a favorable safety profile characterized by an absence of key safety concerns typically associated with a Top1i class. Phase 1 trials for PTK7-directed HWK-007 and MUC16-directed HWK-016 are advancing through dose-escalation, with data expected in the first half of 2027.

Whitehawk Therapeutics announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity financing that is expected to result in gross proceeds of approximately $87.5M, before deducting placement agent fees and other private placement expenses. The PIPE financing includes participation from existing investors including Avoro Capital, QVT, Coastlands Capital, KVP Capital, ADAR1 Capital Management, Acuta Capital Partners, StemPoint Capital LP, Invus, as well as members of the company's executive team. Pursuant to the terms of the securities purchase agreement, Whitehawk is selling an aggregate of (i) 4,330,866 shares of its common stock at a purchase price of $3.92 per share, and (ii) pre-funded warrants to purchase 17,991,021 shares of common stock at a purchase price of $3.9199 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.0001 per share. The PIPE financing is expected to close on May 14, subject to the satisfaction of customary closing conditions. Jefferies and Leerink Partners are acting as lead placement agents for the PIPE financing. Oppenheimer & Co., Citizens Capital Markets and Jones are also acting as placement agents for the PIPE financing.